European Economic
and Social Committee
Specific rules relating to medicinal products for human use intended to be placed on the market of Northern Ireland
Background
The proposed regulation sets out a comprehensive set of joint solutions agreed between the EU and the UK, providing derogations from certain obligations concerning certain medicinal products for human use made available in the UK in respect of Northern Ireland.
Jack O'Connor, EESC member and rapporteur of the opinion, highlighted: The proposed regulation is designed to ensure continuity of supply of medicinal products for human use in Northern Ireland, thus enhancing the prospects for implementation of the Protocol of Ireland/Northern Ireland. In other words, these solutions will allow manufacturers to maintain batch testing and regulatory functions in parts of the UK rather than transferring them to Northern Ireland.
Furthermore, the opinion recommends that the European institutions be updated periodically on the progress of implementation ahead of January 2025, which is set as the target implementation date.
Key points
In the opinion the EESC:
- supports the adoption and early implementation of the proposed regulation, which would ensure continuity of supply of medicinal products for human use in Northern Ireland;
- agrees that it is essential that the proposed regulation contains a provision enabling suspension of the specific rules by the Commission in the event of the UK's non-compliance;
- encourages ongoing consultation with key stakeholders to help ensure timely implementation as well as monitoring for any future risks to the delivery of the objectives of the proposed regulation.
The full text of the opinion can be found here
Additional Information
EESC section: External Relations Section (REX)
Opinion type: Mandatory
Rapporteur: Jack O'Connor
Reference: REX/574-EESC-2023
Referral:COM(2023) 122 final 2023/0064 COD
Date of adoption by section: Not discussed in the section -urgent request
Date of adoption in plenary: 27 April 2023
Result of the vote: 154 in favor/0 against/0 abstentions
Contact
Millie Tsoumani, Press officer
Tel.:+32 2 546 9088, email: Amalia.tsoumani@eesc.europa.eu
Sveto Trajkovski, Policy officer, Administrator
Tel.:+32 2 546 9075, email: Sveto.Trajkovski@eesc.europa.eu
Work organisation
Recommended for you
Specific rules relating to medicinal products for human use intended to be placed on the market of Northern Ireland
Opinion
In accordance with the EU-UK Withdrawal Agreement, Regulation (EC) No 726/2004 and Directive 2001/83/EC as well as the Commission acts based on them, apply to and in the UK in respect of Northern…
Specific rules relating to the entry into Northern Ireland from other parts of the United Kingdom of certain consignments of goods
News
Background The UK and certain UK-based stakeholders have voiced serious concerns that the Withdrawal Agreement imposes a disproportionately high administrative burden on the entry into Northern…
Medicinal products for human and investigational use / Derogations
Opinion
The EESC:welcomes this package of measures;recognises that need to pay particular attention to the situation of smaller EU Member States, Cyprus, Ireland and Malta in particula;stresses in particular…
Specific rules relating to the entry into Northern Ireland from other parts of the United Kingdom of certain consignments of goods
Opinion
In accordance with the EU-UK Withdrawal Agreement, a number of EU legislative acts concerning sanitary and phytosanitary (SPS) measures apply to and in the UK in respect of Northern Ireland after the…
Packaging and labelling of veterinary medicinal products – transitional rules
Opinion
Since the Committee endorses the content of the proposal and feels that it requires no comment on its part, it decided, at its 568th plenary session of 23 and 24 March 2022 (meeting of 23 March), to…